Biogen stock surges 37% after receiving FDA approval for Alzheimer’s drug

June 8, 2021 June 8, 2021 / 3 minutes of reading / By Tyger Fitzpatrick

Longterm shareholders of Biogen (NASDAQ:BIIB) rejoice today after the company received accelerated approval from the FDA for their Alzheimer’s treatment ADUHELM™. The approval marks a historic day as ADUHELM becomes the first treatment to receive approval that addresses an underlying pathology of the disease. Looking ahead, Biogen will “conduct a controlled trial to verify the …

Biogen stock surges 37% after receiving FDA approval for Alzheimer’s drug Read More »

BNGO stock forecast for 2021 and beyond

February 8, 2021 August 8, 2021 / 3 minutes of reading / By Tyger Fitzpatrick

BioNano Genomics Inc (NASDAQ: BNGO) has had a remarkable year of trading, gaining over 979% over the past two months. The company operates in the analytical instruments field, in particular cytogenomics. Simply put, this is the detection of genetic disorders by analyzing the variances in chromosomes. BioNano have developed the Saphyr platform, which has been a …

BNGO stock forecast for 2021 and beyond Read More »

VXRT stock surges 116% – analysts maintain buy rating

February 2, 2021 February 2, 2021 / 3 minutes of reading / By Tyger Fitzpatrick

Vaxart Inc (NASDAQ: VXRT) has seen a remarkable year on Wallstreet after investors rallied behind its experimental COVID-19 vaccine. VXRT stock has gained some serious ground over the past year, surging over 1,559% YTD. Unlike other COVID-19 vaccine candidates, the vaccine is administered orally and can be stored at room temperature. Analysts are certainly bullish …

VXRT stock surges 116% – analysts maintain buy rating Read More »

Analysts maintain buy rating on SRNE stock

January 28, 2021 September 22, 2021 / 3 minutes of reading / By Tyger Fitzpatrick

Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of investors as analysts remain confident in the companies 12 month outlook. The stock has performed well as of late, posting a 29% gain over the past month of trading. Furthermore, the average 12 month price target amongst Wallstreet analysts is $29.67 a share. This suggests …

Analysts maintain buy rating on SRNE stock Read More »

IPOC closes in on merger with Clover Health – now what?

December 29, 2020 December 29, 2020 / 4 minutes of reading / By Tyger Fitzpatrick

Social Capital Hedosophia (NYSE: IPOC) are set to close in on their merger with Clover Health in early 2021. Evidently, this has caused a strong upswing in investor momentum in IPOC’s trading price. IPOC has gained 33% over the past week of trading and 66% for the month of December. The Special Purpose Acquisition Company …

IPOC closes in on merger with Clover Health – now what? Read More »

Moderna and Novavax surge ahead of 2021 – here’s what you need to know

December 6, 2020 December 6, 2020 / 6 minutes of reading / By Tyger Fitzpatrick

The past two weeks have seen a large shift in investor sentiment towards these two key COVID vaccine pioneers. Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) have seen a recent surge in the share price. The companies saw an increase of 26.52% (NVAX) and 38.26% (MRNA) respectively over the past week of trading. …

Moderna and Novavax surge ahead of 2021 – here’s what you need to know Read More »

iBio’s stock forecast for 2021 and beyond

October 5, 2020 August 8, 2021 / 4 minutes of reading / By Tyger Fitzpatrick

iBio inc. (NYSE:IBIO) rose to popularity amongst the investor community as they announced their intentions to develop a COVID-19 vaccine. The stock is currently trading 586% higher since the beginning of 2020. However since July, iBio stock has been on a downward slope which has since found a new equilibrium at $2. The initial announcement of …

iBio’s stock forecast for 2021 and beyond Read More »

SRNE stock forecast indicates a bullish 2021 – is it real or COVID-19 hype?

September 27, 2020 August 8, 2021 / 4 minutes of reading / By Patrick McLoughlin

Sorrento Therapeutics (NASDAQ: SRNE) was lacking direction as short-sellers brought down the stock after most positive announcements. However, the green light from the FDA allows the bulls to lay down the trackwork. The clear path is promising, but the volatility is making it difficult for investors to enter. Today’s article looks to make sense of …

SRNE stock forecast indicates a bullish 2021 – is it real or COVID-19 hype? Read More »

CVS stock forecast 2021 – will the healthcare giant bounce back?

September 26, 2020 August 18, 2021 / 5 minutes of reading / By Patrick McLoughlin

CVS Health (NASDAQ: CVS) stock has been going on a rollercoaster ride in 2020 so far. The start of the year was promising as the healthcare giant hit 52-week highs. Unfortunately, COVID-19 sent CVS spiraling down. Investors are currently unsure what is in store for CVS come 2021 and beyond. Especially, as the CVS stock …

CVS stock forecast 2021 – will the healthcare giant bounce back? Read More »

INO surges 10% pre-market – here’s what you need to know

September 16, 2020 October 6, 2020 / 4 minutes of reading / By Tyger Fitzpatrick

Inovio (NASDAQ:INO) is set to open 10% higher this morning after the promising address by CEO & President Dr. Joseph Kim on the H.C Wainwright 22nd Annual Investment Conference. Dr. Kim advised that the initiation of Phase 2 trials for their COVID-19 vaccine INO-4800 is on track to commence later this month. The CEO also …

INO surges 10% pre-market – here’s what you need to know Read More »

Pharmaceutical and Biotechnological Stocks

Stay Connected